Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anand Devaraj

Showing results (91-100 of 170) with videos related to

Pageof 17
Sort By:
Thorax|August 6, 2024
Artificial stone silicosis: a UK case seriesJohanna Feary, Anand Devaraj, Matthew Burton, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2025
AI performance for nodule volume doubling time in the follow-up of the UKLS lung cancer screening study compared to expert consensus and histological validationBeibei Jiang, Harriet L Lancaster, Michael P A Davies, et al.
The Lancet. Respiratory Medicine|March 9, 2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U Wells, Kevin R Flaherty, Kevin K Brown, et al.
ERJ Open Research|February 13, 2024
Overnight desaturation in interstitial lung diseases: links to pulmonary vasculopathy and mortalityGeorge A Margaritopoulos, Athanasia Proklou, Athina Trachalaki, et al.
The European Respiratory Journal|July 2, 2021
Effects of nintedanib by inclusion criteria for progression of interstitial lung diseaseToby M Maher, Kevin K Brown, Michael Kreuter, et al.
BMJ Open Respiratory Research|October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
The European Respiratory Journal|September 3, 2021
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trialKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
Lung Cancer (Amsterdam, Netherlands)|March 10, 2026
Volume and location of screen-detected lung nodules associated with lung cancer within two-year follow-up: Post hoc analysis from the UK Lung Cancer Screening (UKLS) trialOke Dimas Asmara, Harriet L Lancaster, John K Field, et al.
Chest|August 6, 2022
Immediate, Remote Smoking Cessation Intervention in Participants Undergoing a Targeted Lung Health Check: Quit Smoking Lung Health Intervention Trial, a Randomized Controlled TrialParris J Williams, Keir E J Philip, Navjot Kaur Gill, et al.
Critical Care Medicine|January 20, 2021
Prevalence of Thrombotic Complications in ICU-Treated Patients With Coronavirus Disease 2019 Detected With Systematic CT ScanningSaeed Mirsadraee, Diana A Gorog, Ciara F Mahon, et al.
Pageof 17

Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
Thorax|August 6, 2024
Artificial stone silicosis: a UK case seriesJohanna Feary, Anand Devaraj, Matthew Burton, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2025
AI performance for nodule volume doubling time in the follow-up of the UKLS lung cancer screening study compared to expert consensus and histological validationBeibei Jiang, Harriet L Lancaster, Michael P A Davies, et al.
The Lancet. Respiratory Medicine|March 9, 2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U Wells, Kevin R Flaherty, Kevin K Brown, et al.
ERJ Open Research|February 13, 2024
Overnight desaturation in interstitial lung diseases: links to pulmonary vasculopathy and mortalityGeorge A Margaritopoulos, Athanasia Proklou, Athina Trachalaki, et al.
The European Respiratory Journal|July 2, 2021
Effects of nintedanib by inclusion criteria for progression of interstitial lung diseaseToby M Maher, Kevin K Brown, Michael Kreuter, et al.
BMJ Open Respiratory Research|October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
The European Respiratory Journal|September 3, 2021
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trialKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
Lung Cancer (Amsterdam, Netherlands)|March 10, 2026
Volume and location of screen-detected lung nodules associated with lung cancer within two-year follow-up: Post hoc analysis from the UK Lung Cancer Screening (UKLS) trialOke Dimas Asmara, Harriet L Lancaster, John K Field, et al.
Chest|August 6, 2022
Immediate, Remote Smoking Cessation Intervention in Participants Undergoing a Targeted Lung Health Check: Quit Smoking Lung Health Intervention Trial, a Randomized Controlled TrialParris J Williams, Keir E J Philip, Navjot Kaur Gill, et al.
Critical Care Medicine|January 20, 2021
Prevalence of Thrombotic Complications in ICU-Treated Patients With Coronavirus Disease 2019 Detected With Systematic CT ScanningSaeed Mirsadraee, Diana A Gorog, Ciara F Mahon, et al.
Pageof 17